Metraipolis › archive › dc_05f031a8deeb

First-line therapy of osimertinib with chemotherapy in Chinese patients with EGFR mutation-positive non-small cell lung cancer: protocol for a multicenter,… — Europe PMC PMID:40978050

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40978050
DOI
10.3389/fonc.2025.1625714
License (as archived)
solo-consultazione
Archived
2026-11-10T03:07:06.693Z
SHA-256 of the archived text
82e50ac86ea28742665624c356ad832bd1cc1c2f8073cf854c6bfb0fb7f02cb4
Stable URL of this page
https://metraipolis.com/documento/dc_05f031a8deeb

How to cite

First-line therapy of osimertinib with chemotherapy in Chinese patients with EGFR mutation-positive non-small cell lung cancer: protocol for a multicenter,… — Europe PMC PMID:40978050 — Europe PMC (en), https://europepmc.org/article/MED/40978050 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_05f031a8deeb (Metraipolis archive dc_05f031a8deeb, sha256 82e50ac86ea28742665624c356ad832bd1cc1c2f8073cf854c6bfb0fb7f02cb4)
BibTeX
@misc{dc05f031a8deeb,
  title = {First-line therapy of osimertinib with chemotherapy in Chinese patients with EGFR mutation-positive non-small cell lung cancer: protocol for a multicenter,… — Europe PMC PMID:40978050},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40978050},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_05f031a8deeb; sha256 82e50ac86ea28742665624c356ad832bd1cc1c2f8073cf854c6bfb0fb7f02cb4},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40978050. Agents can read the archived copy with the MCP tool read_document.